Lisata Therapeutics (NASDAQ:LSTA) Shares Up 1.4% – Here’s Why

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares traded up 1.4% during trading on Wednesday . The stock traded as high as $2.98 and last traded at $2.98. 45,386 shares were traded during trading, an increase of 215% from the average session volume of 14,403 shares. The stock had previously closed at $2.94.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Stock Up 1.4 %

The company has a market cap of $25.02 million, a P/E ratio of -1.19 and a beta of 1.16. The business has a 50-day moving average price of $2.83 and a two-hundred day moving average price of $3.04.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same period last year, the business earned ($0.65) earnings per share. As a group, sell-side analysts expect that Lisata Therapeutics, Inc. will post -2.66 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP lifted its stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. 8.94% of the stock is owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.